DNA vaccine aims to train immune system against breast cancer

NCT ID NCT00393783

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether a DNA vaccine made from a rat HER2 gene can safely stimulate the immune system in people with advanced or high-risk HER2-positive breast cancer. Thirteen participants receive multiple injections of the vaccine at different doses. The main goal is to check safety and see if the body produces an immune response against HER2.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rat HER2 DNA vaccine
What this could lead to: If successful, this could point toward a new way to help the immune system fight HER2-positive breast cancer, potentially slowing disease progression.
What could go wrong: This is a very early phase 1 trial with only 13 participants, so it is primarily testing safety, not effectiveness. The immune response may not be strong enough to shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.